Trial Profile
A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms LANTERN
- Sponsors Ipsen
- 27 Feb 2017 Status changed from active, no longer recruiting to completed.
- 30 Jun 2016 Planned End Date changed from 1 Apr 2017 to 1 Jan 2017.
- 30 Jun 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Nov 2016.